Shares of depression drug-focused GH Research PLC (GHRS) have surged 25% to $20.10, well above its IPO price of $16 per share in its first trading session.
Read More
Shares of depression drug-focused GH Research PLC (GHRS) have surged 25% to $20.10, well above its IPO price of $16 per share in its first trading session.
Read More
